#United States #Indianapolis #Zepbound #Shaquille O'Neal #Obstructive Sleep Apnea

Shaquille O'Neal Joins Eli Lilly in National Campaign for Sleep Apnea Awareness

In a groundbreaking initiative aimed at raising awareness about obstructive sleep apnea (OSA), basketball legend and cultural icon Shaquille O'Neal has teamed up with Eli Lilly and Company to launch the national campaign titled "Watch This." The initiative comes after O'Neal learned that the symptoms he had been experiencing for years — fatigue, loud snoring, and concentration difficulties — are indicative of moderate-to-severe OSA, a serious condition that affects approximately 24 million adults in the United States, particularly those living with obesity.

The Journey to Diagnosis

For O'Neal, living with OSA was a reality he long ignored, attributing his exhaustion and disrupted sleep to his larger physique. "For a long time, I was tired during the day, not sleeping well at night, and I just thought that's how it was for someone my size," he explained. However, after a thorough evaluation, O'Neal was diagnosed with moderate obstructive sleep apnea, realizing that what he considered normal was, in fact, a significant health issue.

Eli Lilly's Zepbound® (tirzepatide) is the first and only prescription medication designed specifically for treating moderate-to-severe OSA in adults affected by obesity. The medication works best in conjunction with a reduced-calorie diet and increased physical activity. In clinical trials, Zepbound has shown effectiveness in significantly reducing breathing interruptions during sleep, and even led to complete resolution of symptoms for some individuals after just one year of treatment.

The severity and often-overlooked nature of OSA can be alarming; many individuals remain undiagnosed, unaware of the serious implications it can have on their health. O'Neal aims to change that narrative. "If sharing my story helps even one person talk to their doctor, that's a win," he commented.

The Launch of the Campaign

"Watch This" comprises a national, multi-channel outreach strategy that includes broadcast and streaming ads, digital messaging, and community events where O'Neal engages with potential patients directly. The campaign's main goal is to address the awareness gap concerning the symptoms and dangers of OSA, as well as to guide individuals to necessary medical attention and treatment options. O'Neal shares his story in candid terms, detailing the journey from symptoms to diagnosis and the subsequent positive changes he experienced after starting Zepbound treatment.

"Millions of people are living with moderate-to-severe OSA and may experience snoring, daytime sleepiness, and irritability," said Lina Polimeni, senior vice president and chief marketing officer at Lilly. The frankness of O'Neal’s story resonates with many and opens the dialog on a subject that is often stigmatized or misunderstood.

By sharing his personal experience, O'Neal places a face on the problems of OSA, encouraging individuals who have been experiencing similar symptoms to engage in conversations with their healthcare providers. The campaign also directs viewers to resources available at zepbound.lilly.com, reinforcing the importance of early detection and intervention.

Moving Toward Healthier Futures

Eli Lilly continues to assert its commitment to enhancing cardiometabolic health through innovative treatments and patient access. O’Neal's collaboration marks a pivotal step in moving those affected by OSA from symptoms to diagnosis, and ultimately, into effective care. The inclusion of a celebrity like O'Neal serves as a vital bridge, breaking down barriers and encouraging open discussions about sleep apnea and its treatments.

In a world where many may feel isolated with their conditions, O'Neal's initiative fosters community awareness and brings hope to countless individuals battling this hidden disorder. By leveraging his platform and sharing his authenticity, he underscores that recognizing health issues is the first step towards achieving better health outcomes, notably in socioeconomic settings.

Thus, the launch of the "Watch This" campaign stands not merely as a promotional effort for a medication but as a universal call to action for health awareness, encouraging everyone to reflect on their own health and seek help when necessary. Through the support of partnerships like these, Eli Lilly continues to transform the lives of individuals managing chronic health conditions, creating pathways to healthier, more fulfilling lives.